Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2022 09:59 ET | Source: Scynexis

SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences

JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
March 29, 2022 07:00 ET | Source: Scynexis

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BREXAFEMME® (ibrexafungerp tablets), launched in August 2021, achieved net revenues of $1.1 million in 2021. Fourth quarter 2021 net revenues were $0.6 million.As of the end of 2021, BREXAFEMME was...
March 24, 2022 08:30 ET | Source: Scynexis

SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
March 08, 2022 08:30 ET | Source: Scynexis

SCYNEXIS Named to Fast Company’s 2022 Top 50 List of the World’s Most Innovative Companies

JERSEY CITY, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
March 04, 2022 17:00 ET | Source: Scynexis

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., March 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
March 02, 2022 08:30 ET | Source: Scynexis

SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
February 10, 2022 07:36 ET | Source: Scynexis

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022

Ibrexafungerp, the only fungicidal oral treatment for vaginal yeast infections, successfully achieved statistically significant superiority over placebo for the primary and key secondary study...
February 03, 2022 16:15 ET | Source: Scynexis

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
January 06, 2022 13:03 ET | Source: Scynexis

SCYNEXIS to Participate in Upcoming January Investor Conferences

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
December 22, 2021 08:30 ET | Source: Scynexis

SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million

JERSEY CITY, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...